

F. No. 12(7)/2017/DP/NPPA/Div.II / Vol-IV
National Pharmaceutical Pricing Authority

Subject: Minutes of the 33rd meeting of Multidisciplinary Committee of Experts held on 21.06.2021 at 12:00 noon in NPPA

33rd meeting of the "Multidisciplinary Committee of Experts" was held on 21.06.2021 under the Convenorship of Sh. N.I. Chowdhury, Adviser (Cost), in NPPA. The following members attended the meeting through video conferencing:-

1. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi
2. Dr. Rakesh K. Singh, Assoc. Professor, NIPER, Raebareli
3. Shri A. K. Pradhan, Dy. Drugs Controller, CDSCO
4. Dr. Jai Prakash, Sr. Principal Scientific Officer, Indian Pharmacopoeia Commission
5. Dr. Pooja Gupta, Asso. Prof. Pharmacology, AIIMS, New Delhi

The following officers of NPPA attended and presented the cases to the Committee

1. Sh. S. S. Ojha, Jt. Director (Pricing), NPPA
2. Sh. Prasenjit Das, Deputy Director (Pricing), NPPA
3. Sh. Mahaveer Saini, Deputy Director (Pricing & Monitoring), NPPA

Dr. S. E. Reddy, Jt. Drug Controller, CDSCO was invited as a special invitee in connection with the agenda relating to Amphotericin B (emulsion) 50mg injection.

1. Agenda No. 1 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5 mg + Metformin Hydrochloride IP (extended release) 1000 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer).

1.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:

"(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.

(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were

earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers."

1.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated bilayered tablet containing Dapagliflozin 5 mg + Metformin Hydrochloride IP (in extended release form) 1000 mg at Rs. 7.54 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 5 mg and Metformin Hydrochloride (Extended Release) 1000 mg tablet was earlier approved. The Committee also noted that the applicant company has claimed price of Rs. 8.04 per tablet excluding GST.

1.3 Accordingly, the Committee recommended the retail price of each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5 mg + Metformin Hydrochloride IP (extended release) 1000 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer) at Rs. 7.54 per tablet excluding GST.

2. Agenda No. 2 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP (in extended release form) 1000 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer).

2.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:

"(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.



(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers.”

2.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated bilayered tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP (in extended release form) 1000 mg at Rs. 11.30 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 1000 mg tablet was earlier approved. The Committee also noted that the applicant company has claimed price of Rs. 11.53 per tablet excluding GST.

2.3 Accordingly, the Committee recommended the retail price of each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP (in extended release form) 1000 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer) at Rs. 11.30 per tablet excluding GST.

3. Agenda No. 3 – Retail price fixation under Para 5 of DPCO, 2013 - Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP (extended release) 500 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer).

3.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:

“(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.

(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers.”

3.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated bilayered tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP (in extended release form) 500 mg at Rs. 9.78 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500 mg tablet was earlier approved. The Committee also noted that the applicant company has claimed price of Rs. 9.98 per tablet excluding GST.

3.3 Accordingly, the Committee recommended the retail price of each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10 mg + Metformin Hydrochloride IP (in extended release form) 500 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer) at Rs. 9.78 per tablet excluding GST.

4. Agenda No. 4 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5 mg + Metformin Hydrochloride IP (extended release) 500 mg for M/s Synkem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer)

4.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:


“(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.

(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers.”

4.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated bilayered tablet containing Dapagliflozin 5 mg + Metformin Hydrochloride IP (in extended release form) 500 mg at Rs. 6.25 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 5 mg and Metformin Hydrochloride (Extended Release) 500 mg tablet was earlier approved. The Committee also noted that the applicant company has claimed price of Rs. 6.65 per tablet excluding GST.

4.3 Accordingly, the Committee recommended the retail price of each film coated bilayered tablet containing Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5 mg + Metformin Hydrochloride IP (in extended release form) 500 mg for M/s Synokem Pharmaceuticals Ltd. (manufacturer) and M/s Mankind Pharma Ltd. (marketer) at Rs. 6.25 per tablet excluding GST.



5. Agenda No. 5 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP/USP 1000 mg (extended release) for M/s MSN Laboratories Pvt. Ltd. (manufacturer) and M/s J.B. Chemicals & Pharmaceuticals Ltd. (marketer)

5.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:

“(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.

(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers.”

5.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP/USP (in extended release form) 1000 mg at Rs. 11.30 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 1000 mg tablet was earlier approved. The Committee also noted that the applicant company has claimed price of Rs. 15.40 per tablet.

5.3 Accordingly, the Committee recommended the retail price of each film coated tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP/USP 1000 mg

(extended release) for M/s MSN Laboratories Pvt. Ltd. (manufacturer) and M/s J.B. Chemicals & Pharmaceuticals Ltd (marketer) at Rs. 11.30 per tablet excluding GST.

6. Agenda No. 6 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP/USP 500 mg (extended release) for M/s MSN Laboratories Pvt. Ltd. (manufacturer) and M/s J.B. Chemicals & Pharmaceuticals Ltd. (marketer)

6.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:

“(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.

(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers.”

6.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP/USP (in extended release form) 500 mg at Rs. 9.78 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500 mg tablet was earlier approved. The Committee also noted that the applicant company has claimed price of Rs. 14.20 per tablet.

6.3 Accordingly, the Committee recommended the retail price of each film coated tablet containing Dapagliflozin 10 mg + Metformin Hydrochloride IP/USP 500 mg (extended release) for M/s MSN Laboratories Pvt. Ltd. (manufacturer) and M/s J.B. Chemicals & Pharmaceuticals Ltd (marketer) at Rs. 9.78 per tablet excluding GST.

7. Agenda No. 7 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated tablet containing Dapagliflozin 5 mg + Metformin Hydrochloride IP/USP 1000 mg (extended release) for M/s MSN Laboratories Pvt. Ltd. (manufacturer) and M/s J.B. Chemicals & Pharmaceuticals Ltd. (marketer)

7.1 The Committee noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug. The Committee further noted that the Authority in its 82nd meeting dated 23.12.2020 approved the retail price of Fixed Dose Combinations (FDCs) of Dapagliflozin 10 mg and Metformin Hydrochloride (Extended Release) 500/1000 mg tablet as per the methodology described below:

"(i) The Authority noted that the applications have been received for retail price fixation of Fixed Dose Combinations (FDCs) of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet. The Authority further noted that the Patent of Dapagliflozin has expired on 02.10.2020 making it an off-patent drug.

(ii) The Authority recalled the decision taken in its 72nd meeting dated 20.01.2020 regarding retail price fixation of Fixed Dose Combinations (FDCs) of Metformin and Vildagliptin tablets in which it emphasized that the benefit of price reduction in case of formulations becoming off-patent ought to be passed on to the consumers in public interest and decided to fix the retail price of FDCs of Metformin and Vildagliptin tablet by adding 16% retailer margin to the average Price to Retailer (PTR) based on Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Metformin and Vildagliptin tablets to give the benefits of patent expiry of the drug Vildagliptin to consumers.

(iii) The Authority deliberated upon the matter in detail and decided to fix the retail price of FDC of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablets in line with the decision taken in the 72nd meeting 20.01.2020 regarding retail price fixation of FDC of Metformin and Vildagliptin tablets. (iv) Accordingly, the Authority approved retail price fixation of FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet by adding 16% retailer margin to the average Price To Retailer (PTR) based on the Form-V data submitted by the companies for whom retail prices were earlier approved for FDCs of Dapagliflozin and Metformin Hydrochloride (Extended Release) tablet in public interest so as to extend the benefit of price reduction due to patent expiry to the consumers."

7.2 The Committee deliberated upon the matter in detail and decided to derive the retail price of each film coated tablet containing Dapagliflozin 5 mg + Metformin Hydrochloride IP/USP (in extended release form) 1000 mg at Rs. 7.54 per tablet, in line with the decisions taken by the Authority in its 82nd meeting dated 23.12.2020, by taking data as per Form-V submitted by the companies to which the retail price for the Fixed Dose Combinations (FDCs) of Dapagliflozin 5 mg and Metformin Hydrochloride (Extended Release) 1000 mg tablet was earlier approved. The

Committee also noted that the applicant company has claimed price of Rs. 11.50 per tablet.

7.3 Accordingly, the Committee recommended the retail price of each film coated tablet containing Dapagliflozin 5 mg + Metformin Hydrochloride IP/USP 1000 mg (extended release) for M/s MSN Laboratories Pvt. Ltd. (manufacturer) and M/s J.B. Chemicals & Pharmaceuticals Ltd (marketer) at Rs. 7.54 per tablet excluding GST.

8. Agenda No. 8 - Retail price fixation under Para 5 of DPCO, 2013-Human Coagulation Factor IX Freeze dried IP 1200 IU for M/s Baxalta Bioscience India Pvt. Ltd. (manufacturer/importer and marketer)

8.1 The Committee deliberated upon the matter in detail and recommended the retail price of each Human Coagulation Factor IX Freeze dried IP 1200 IU for M/s Baxalta Bioscience India Pvt. Ltd. (manufacturer/importer and marketer) at Rs. 20996.50 per pack excluding GST as detailed below:

a. Present applicable ceiling Price for Coagulation Factor IX Powder for Injection 600 IU = 12350.88 per pack excluding GST

b. Derived retail price as per recommendation of pronab sen committee :

$$P(s) = P^*.[1+a.\{(s-s^*)/s^*\}]$$

where : P(s) = Price ceiling of the strength s,

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength


a= 0.8 for pack / capsule and 0.7 for injectibles.

c. Working of Retail Price of Human Coagulation Factor IX 1200IU per Pack

Derived Retail price for Human Coagulation Factor IX 1200 IU = $12350.88[1+0.7\{(1200-600)/600\}] = \text{Rs. } 20996.50$ per pack

9. Agenda No. 9 - Retail price fixation under Para 5 of DPCO, 2013-Combipack of (a) Trastuzumab lyophilized powder for concentrate for solution for infusion vial 375 mg and (b) Bacteriostatic Water for Injection USP 20 ml Vial for M/s Intas Pharmaceuticals Ltd. (manufacturer and marketer).

9.1 The Committee deliberated upon the matter in detail and recommended the retail price of each Combipack of (a) Trastuzumab lyophilized powder for concentrate for solution for infusion vial 375 mg and (b) Bacteriostatic Water for Injection USP 20 ml Vial for M/s Intas Pharmaceuticals Ltd. (manufacturer and marketer) at Rs. 17500 per vial excluding GST as detailed below:



a. Worked out Price

Retail price provided for Trastuzumab 150 mg vial at Rs: 15526.97 per vial excluding GST vide SO. 2334(E) dated 15.06.2021.

Derived retail price as per recommendation of Pronab Sen committee:

$$P(s) = P^*.[1+a.\{(s-s^*)/s^*\}]$$

Where : P(s) = Price ceiling of the strength s,
P* = price ceiling for reference strength s*
s = strength in terms of API content
s* = reference strength
a= 0.8 for pack / capsule and 0.7 for injectibles.

Derived Retail price for Trastuzumab 375 mg/50 ml Pack = $15526.97[1+0.70\{(375-150)/150\}]$ = Rs. 31830.29 per pack

b. Retail price claimed by M/s Intas Pharmaceuticals Ltd Rs. 17500.00 per vial


c. Recommended retail price =Rs. 17500.00 per vial excluding GST

9.2 The Committee further noted that the retail price claimed by M/s Intas Pharmaceuticals Ltd for Combipack of (a) Trastuzumab lyophilized powder for concentrate for solution for infusion vial 375 mg and (b) Bacteriostatic Water for Injection USP 20 ml Vial at Rs. 17500 per vial and recommended to examine the price of Trastuzumab 150 mg vial Injection/ Infusion in this regard.

10. Agenda No. 10 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 2.5 mg + Metformin Hydrochloride IP 500 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer)

10.1 The Committee noted that the patent of formulation 'Saxagliptin' has expired on 05.03.2021. Accordingly, the retail price of the Fixed Dose Combinations (FDCs) of Metformin + Saxagliptin tablet, if calculated based on six month prior market data, the price of the patented period would be taken into consideration and hence the benefits of price rationalisation due to expiry of the patent would not be pass on to the patients.

10.2 The Committee also noted that the MRP of FDCs of 'Vildagliptin+Metformin' tablet which was in the range of Rs. 25.00-Rs. 27.00 per tablet during the patented period came in the range of Rs. 7.00-9.00 per tablet after the expiry of the patent. The Committee also observed that the MRP of FDCs of 'Dapagliflozin + Metformin' tablet which was in the range of Rs. 56.00-Rs. 57.00 per tablet during the patent period came in the range of Rs. 11.00-Rs.12.00 per tablet after the expiry of the patent. The Committee observed that there is considerable reduction in the price of the drug after the expiry of the Patent.



10.3 The Committee deliberated upon the matter in detail and is of the opinion that the price of the drugs be reduced on the expiry of the patent so as to pass on the benefits of price reduction due to expiry of the patent to the patients. Accordingly, the Committee recommended that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Saxagliptin' to arrive at the retail price.

10.4 The Committee further deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 2.5 mg + Metformin Hydrochloride IP 500 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer) at Rs. 17.70 per tablet excluding GST in line with the matter enumerated in Para 10.3 above, as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Composition – Each film coated tablet containing Saxagliptin Hydrochloride eq. To Saxagliptin 2.5 mg + Metformin Hydrochloride IP 500 mg (As extended release)		
(a)	Derived retail price of Saxagliptin 2.5 mg	Retail price (as per September, 2020 data)	32.32
(b)	50% of (a)		16.16
(c)	Metformin CR 500 mg	Ceiling Price	1.92
(d)	Sum of (b) + (c)		18.08
(e)	Less: 20% of the lowest of (b) and (c) as recommended in the Pronab Sen Committee report		0.38
(f)	Worked out retail price (d) –(e)		17.70
(g)	Retail price claimed		45.00
(h)	Recommended retail price		17.70

11. Agenda No. 11 - Retail price fixation under Para 5 of DPCO, 2013 - Each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 2.5 mg + Metformin Hydrochloride IP 1000 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer)

11.1 The Committee noted that the patent of formulation 'Saxagliptin' has expired on 05.03.2021. Accordingly, the retail price of the Fixed Dose Combinations (FDCs) of Metformin + Saxagliptin tablet, if calculated based on six month prior market data, the price of the patented period would be taken into consideration and hence the

benefits of price rationalisation due to expiry of the patent would not be pass on to the patients.

11.2 The Committee also noted that the MRP of FDCs of 'Vildagliptin+Metformin' tablet which was in the range of Rs. 25.00-Rs. 27.00 per tablet during the patented period came in the range of Rs. 7.00-9.00 per tablet after the expiry of the patent. The Committee also observed that the MRP of FDCs of 'Dapagliflozin + Metformin' tablet which was in the range of Rs. 56.00-Rs. 57.00 per tablet during the patent period came in the range of Rs. 11.00-Rs.12.00 per tablet after the expiry of the patent. The Committee observed that there is considerable reduction in the price of the drug after the expiry of the Patent.

11.3 The Committee deliberated upon the matter in detail and is of the opinion that the price of the drugs be reduced on the expiry of the patent so as to pass on the benefits of price reduction due to expiry of the patent to the patients. Accordingly, the Committee recommended that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Saxagliptin' to arrive at the retail price.

11.4 The Committee further deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 2.5 mg + Metformin Hydrochloride IP 1000 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer) at Rs. 19.09 per tablet excluding GST in line with the matter enumerated in Para 11.3 above, as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Composition – Each film coated tablet containing Saxagliptin Hydrochloride eq. To Saxagliptin 2.5 mg + Metformin Hydrochloride IP 1000 mg (As extended release)		
(a)	Derived retail price of Saxagliptin 2.5 mg	Retail price (as per September, 2020 data)	32.32
(b)	50% of (a)		16.16
(c)	Metformin CR 1000 mg	Ceiling Price	3.66
(d)	Sum of (b) + (c)		19.82
(e)	Less: 20% of the lowest of (b) and (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out retail price (d) –(e)		19.09
(g)	Retail price claimed		47.50
(h)	Recommended retail price		19.09

12. Agenda No. 12 - Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 5 mg + Metformin Hydrochloride IP 500 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer).

12.1 The Committee noted that the patent of formulation 'Saxagliptin' has expired on 05.03.2021. Accordingly, the retail price of the Fixed Dose Combinations (FDCs) of Metformin + Saxagliptin tablet, if calculated based on six month prior market data, the price of the patented period would be taken into consideration and hence the benefits of price rationalisation due to expiry of the patent would not be pass on to the patients.

12.2 The Committee also noted that the MRP of FDCs of 'Vildagliptin+Metformin' tablet which was in the range of Rs. 25.00-Rs. 27.00 per tablet during the patented period came in the range of Rs. 7.00-9.00 per tablet after the expiry of the patent. The Committee also observed that the MRP of FDCs of 'Dapagliflozin + Metformin' tablet which was in the range of Rs. 56.00-Rs. 57.00 per tablet during the patent period came in the range of Rs. 11.00-Rs.12.00 per tablet after the expiry of the patent. The Committee observed that there is considerable reduction in the price of the drug after the expiry of the Patent.

12.3 The Committee deliberated upon the matter in detail and is of the opinion that the price of the drugs be reduced on the expiry of the patent so as to pass on the benefits of price reduction due to expiry of the patent to the patients. Accordingly, the Committee recommended that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Saxagliptin' to arrive at the retail price.

12.4 The Committee further deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 5 mg + Metformin Hydrochloride IP 500 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer) at Rs. 19.45 per tablet excluding GST in line with the matter enumerated in Para 12.3 above, as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Composition – Each film coated tablet containing Saxagliptin Hydrochloride eq. To Saxagliptin 5 mg + Metformin Hydrochloride IP 500 mg (As extended release)		
(a)	Derived retail price of Saxagliptin 5 mg	Retail price (as per September, 2020 data)	35.81

(b)	50% of (a)		17.91
(c)	Metformin CR 1000 mg	Ceiling Price	1.92
(d)	Sum of (b) + (c)		19.83
(e)	Less: 20% of the lowest of (b) and (c) as recommended in the Pronab Sen Committee report		0.38
(f)	Worked out retail price (d) –(e)		19.45
(g)	Retail price claimed		47.00
(h)	Recommended retail price		19.45

13. Agenda No. 13 - Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (As extended release) for M/s.Morepan Laboratories Ltd. (manufacturer and marketer)

13.1 The Committee noted that the patent of formulation 'Saxagliptin' has expired on 05.03.2021. Accordingly, the retail price of the Fixed Dose Combinations (FDCs) of Metformin + Saxagliptin tablet, if calculated based on six month prior market data, the price of the patented period would be taken into consideration and hence the benefits of price rationalisation due to expiry of the patent would not be pass on to the patients.

13.2 The Committee also noted that the MRP of FDCs of 'Vildagliptin+Metformin' tablet which was in the range of Rs. 25.00-Rs. 27.00 per tablet during the patented period came in the range of Rs. 7.00-9.00 per tablet after the expiry of the patent. The Committee also observed that the MRP of FDCs of 'Dapagliflozin + Metformin' tablet which was in the range of Rs. 56.00-Rs. 57.00 per tablet during the patent period came in the range of Rs. 11.00-Rs.12.00 per tablet after the expiry of the patent. The Committee observed that there is considerable reduction in the price of the drug after the expiry of the Patent.

13.3 The Committee deliberated upon the matter in detail and is of the opinion that the price of the drugs be reduced on the expiry of the patent so as to pass on the benefits of price reduction due to expiry of the patent to the patients. Accordingly, the Committee recommended that a reduction of 50% be allowed on the patented component of FDCs i.e. 'Saxagliptin' to arrive at the retail price.

13.4 The Committee further deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Saxagliptin Hydrochloride eq. to Saxagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (As extended release) for M/s. Morepan Laboratories Ltd. (manufacturer and marketer) at Rs. 20.84 per tablet



excluding GST in line with the matter enumerated in Para 13.3 above, as detailed below:

S. No.	Particulars	Source/Method	Amount (Rs.)
	Composition – Each film coated tablet containing Saxagliptin Hydrochloride eq. To Saxagliptin 5 mg + Metformin Hydrochloride IP 1000 mg (As extended release)		
(a)	Derived retail price of Saxagliptin 5 mg	Retail price (as per September, 2020 data)	35.81
(b)	50% of (a)		17.91
(c)	Metformin CR 1000 mg	Ceiling Price	3.66
(d)	Sum of (b) + (c)		21.57
(e)	Less: 20% of the lowest of (b) and (c) as recommended in the Pronab Sen Committee report		0.73
(f)	Worked out retail price (d) –(e)		20.84
(g)	Retail price claimed		51.00
(h)	Recommended retail price		20.84

14. Agenda No. 14 - Retail price fixation under Para 5 of DPCO, 2013- Each film coated tablet containing Ofloxacin IP 200 mg + Metronidazole IP 500 mg for M/s J.B. Chemicals & Pharmaceuticals Ltd. (manufacturer and marketer)

14.1 Committee deliberated upon the matter in detail and recommended the retail price of each film coated tablet containing Ofloxacin IP 200 mg + Metronidazole IP 500 mg for M/s J.B. Chemicals & Pharmaceuticals Ltd. (manufacturer and marketer) at Rs. 6.72 per tablet as detailed below:

Computation of Retail Price per Tablet	Source/Method	Amount (Rs.)
Composition – Each film coated tablet containing Ofloxacin IP 200 mg + Metronidazole IP 500 mg		
a. Ofloxacin IP 200 mg	Retail price (as per November 2020 data)	5.50
b. Metronidazole IP 500 mg	Retail Price as per Pronab Sen Committee Report	1.52

Worked out Retail Price		7.02
d. Less 20% of the lowest of (a) and (b) as recommended in the Pronab Sen Committee report		0.30
Net Retail Price (a+b-c)		6.72
Company Claimed Price		8.50
Recommended price		6.72

Derived retail price as per recommendation of pronab sen committee:

$$P(s) = P^*.[1+a.\{(s-s^*)/s^*\}]$$

Where : P(s) = Price ceiling of the strength s

P* = price ceiling for reference strength s*

s = strength in terms of API content

s* = reference strength

a= 0.8 for tablet / capsule and 0.7 for injectibles.

Derived Retail Price for Metronidazole IP 500 mg tablet

Ceiling Price of Metronidazole IP 200 Tablet = Rs. 0.69 per tablet


Derived Retail price for Metronidazole IP 500 Tablet = $0.69[1+0.80\{500-200\}/200]$ = Rs. 1.52 per tablet

15. Agenda No. 15 - Application filed by M/s Cipla Ltd for grant of separate price / special price for 'Ciphaler Inhaler Device' under the provisions of para 11(3) of DPCO 2013

15.1 The Committee noted the document submitted by M/s Cipla Ltd in connection with the application for grant of separate price / special price for 'Ciphaler Inhaler Device' under the provisions of para 11(3) of DPCO 2013. The Committee also observed the demonstration given by M/s Cipla Ltd specifying the technical and other details for the product 'Ciphaler Inhaler Device'. The Committee deliberated upon the matter in detail and observed that further examination is required in the matter. Accordingly, the Committee decided that the matter would be deliberated further in the next meeting.

16. Agenda No. 16 - Application by M/s Otsuka Pharmaceuticals India Pvt. Ltd for separate price under Para 11(3) of DPCO 2013 with respect to Metronidazole Injection IP (0.5% w/v) 100ml in Non-glass pack having Special features

16.1 The matter was deferred.



17. Agenda No. 17 - Application by M/s Otsuka Pharmaceuticals India Pvt. Ltd for separate price under Para 11(3) of DPCO 2013 with respect Mannitol Injection 20% in Non-glass pack having Special features

17.1 The matter was deferred.

18. Agenda No. 18 - Application by M/s Otsuka Pharmaceuticals India Pvt. Ltd for separate price under Para 11(3) of DPCO 2013 with respect Dextrose Injection (25% w/v) 100 ml in Non-glass pack having Special features.

18.1 The matter was deferred.

19. Agenda No. 19 - Retail price fixation under Para 5 of DPCO, 2013- Each enteric coated tablet containing Rabeprazole Sodium IP 20 mg+ Ondansetron Hydrochloride IP eq. to Ondansetron 4 mg for M/s Dallas Drugs Pvt. Ltd. (manufacturer) and M/s Alkem Laboratories Ltd. (marketer)

19.1 The Committee deliberated upon the matter in detail and directed that the regulatory status of the new drug be obtained from the applicant company.


20. Agenda No. 20 - Retail price fixation under Para 5 of DPCO, 2013- Each pack of 200 ml oral solution containing Zinc Sulphate Monohydrate IP 0.0110g+ Sodium Citrate IP 0.5800g + Potassium Chloride IP 0.3000g + Sodium Chloride IP 0.5200g + Dextrose Anhydrous IP 2.7000g for M/s Halewood Laboratories Pvt. Ltd. (manufacturer) and M/s FDC Ltd. (marketer)

20.1 The Committee decided to deliberate upon the matter in the next meeting.

21. Agenda No. 21 – Issues relating to pricing of Amphotericin B (Emulsion) 50mg /10 ml injection

21.1 The Committee noted that three variant of Amphotericin B Powder for Injection 50 mg i.e conventional, lipid and liposomal are scheduled formulations under DPCO 2013 and the ceiling price is fixed. The Committee deliberated upon the matter in detail and decided that a clarification be obtained from Central Drugs Standard Control Organisation (CDSCO) as to whether Emulsion form of Amphotericin B has major difference from Lipid form to consider a separate price for it or ceiling price notified for Amphotericin B (Lipid) may also be extended to Amphotericin B (Emulsion).

The meeting ended with a vote of thanks to all.


(S. S. Ojha)
Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on November, 2020 Date under Para 4 of DPCO, 2013

Each firm coated tablet containing Ofloxacin 200 mg for M/s Windax Biotech Pvt. Ltd. (manufacturer) and M/s J.B Chemicals & Pharmaceuticals Ltd. (marketer)	Number of Companies constituting Market Share of 1% & Above		10
	Sum of MAT value considered for price calculation (In lakhs)		8,607.98
	Sum of PTR per unit considered for price calculation		47.38
	Number of Packs considered		10
	Average PTR		4.74
	Add: 10% Retailer Margin		0.78
Retail Price (without local taxes)		5.50	
% Reduction with compared to Highest Price		19.93%	

Minimum Price (Rs.)	1.46
Maximum Price (Rs.)	5.92
Average of all considered (Rs.)	4.74
Retail Price (Rs.)	5.5

S.No.	बिक्रि विवरण Pack Description	उत्प BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT	909,584,315		100%		M3		Price per Unit (Rs.)	Price per Unit (Rs.) Considered
							PTR(Rs.)	MAT(Rs.)	SKU wise MAT %	Brandwis e MAT (ignoring 0% MAT)	Quality (Y/N) Y=Yes N=No	Price per Unit (Rs.)			
1	ACFLOX 200 MG TABLET 10	ACFLOX	ACRON PHARMACEUTICALS	200 MG	10	TABLET	30.7	71199.3	0.01%	0.01%	N	3.07			
2	AFLOX 200 MG TABLET 10	AFLOX	APOSTLE REMEDIES	200 MG	10	TABLET	32.47	4838.03	0.00%	0.00%	N	3.25			
3	AGROFLOX 200 MG TABLET 10	AGROFLOX	AGRON REMEDIES PVT. LTD.	200 MG	10	TABLET	27.93	14328.09	0.00%	0.00%	N	2.79			
4	ALOF 200 MG TABLET 10	ALOF	ADMAC PHARMA LTD.	200 MG	10	TABLET	40.8	122.4	0.00%	0.00%	N	4.08			
5	ANOFLOX 200 MG TABLET 10	ANOFLOX	AN PHARMACEUTICALS PVT.LTD.	200 MG	10	TABLET	38.1	205625.7	0.02%	0.02%	N	3.81			
6	ADMIN 200 MG TABLET 10	ADMIN	ELDER PHARMACEUTICALS LTD	200 MG	10	TABLET	42.08	3239230.28	0.36%	0.36%	N	4.21			
7	ATFLOX 200 MG TABLET 10	ATFLOX	ATOPIC LABORATORIES	200 MG	10	TABLET	38.57	546551.67	0.08%	0.08%	N	3.85			
8	ATOFLOX 200 MG TABLET 10	ATOFLOX	ZETA PHARMACEUTICALS	200 MG	10	TABLET	44	24860	0.00%	0.00%	N	4.40			
9	AZOFLOX (MACMILON) 200 MG TABLET 10	AZOFLOX (MACM	MACMILON PHARMACEUTICALS	200 MG	10	TABLET	47.4	1366.8	0.00%	0.00%	N	4.74			
10	BACTER 200 MG TABLET 10	BACTER	CUBIT HEALTHCARE	200 MG	10	TABLET	42.5	32427.5	0.00%	0.00%	N	4.25			
11	BACTIZOLE 200 MG TABLET 10	BACTIZOLE	QUEEN PHARMACEUTICALS	200 MG	10	TABLET	42.58	22822.88	0.00%	0.00%	N	4.28			
12	BACTOF 200 MG TABLET 10	BACTOF	MANVEESH PHARMACEUTICALS LTD	200 MG	10	TABLET	40	95640	0.01%	0.01%	N	4.00			
13	BENZON 200 MG TABLET 10	BENZON	ORGANIC LABORATORIES	200 MG	10	TABLET	41.08	32408.16	0.00%	0.00%	N	4.11			
14	BESTOFLOX 200 MG TABLET 10	BESTOFLOX	BESTOCHEM FORMULATIONS (I) LTD	200 MG	10	TABLET	14.56	2420180.64	2.68%	2.68%	Y	1.46	1.46		
15	BIDOF 200 MG TABLET 10	BIDOF	MEDITIA LABS PVT.LTD	200 MG	10	TABLET	37.14	78088.28	0.01%	0.01%	N	3.71			
16	BIOFF 200 MG TABLET 10	BIOFF	ZYBUS CADILA - ZHL	200 MG	10	TABLET	40.14	3487227.14	0.16%	0.16%	N	4.01			
17	BOXER 200 MG TABLET 10	BOXER	SHRINIVAS GUJARAT LABORATORIES PVT LTD	200 MG	10	TABLET	39.14	28259.08	0.00%	0.00%	N	3.91			
18	BROADBACT 200 MG TABLET 10	BROADBACT	KVI LABS LTD	200 MG	10	TABLET	10	43530	0.00%	0.00%	N	1.00			
19	BRUTAFLOX 200 MG TABLET 10	BRUTAFLOX	MANKIND PHARMACEUTICALS LTD.	200 MG	10	TABLET	43.56	61187.75	0.01%	0.01%	N	4.36			
20	CANOKCIN 200 MG TABLET 10	CANOKCIN	CANVARZYS PHARMACEUTICALS	200 MG	10	TABLET	39.57	2584.89	0.00%	0.00%	N	3.95			
21	DIOFLOX 200 MG TABLET 10	DIOFLOX	DIVINE LIFECARE PVT LTD	200 MG	10	TABLET	39.57	79.92	0.00%	0.00%	N	4.00			
22	ECOFLOX (EAST WEST) 200 MG TABLET 10	ECOFLOX (EAST W	EAST WEST PHARMA	200 MG	10	TABLET	39.96	3777.63	0.00%	0.00%	N	4.71			
23	EFLOX 200 MG TABLET 10	EFLOX	ALGEN HEALTHCARE PVT LTD	200 MG	10	TABLET	47.14	216.98	0.00%	0.00%	N	1.14			
24	ELDEFLOX (ELDER PROJECTS) 200 MG TABLET 10	ELDEFLOX (ELDER	ELDER PROJECTS LIMITED	200 MG	10	TABLET	11.42	1420.77	0.00%	0.00%	N	3.64			
25	ENCIN (ENDOCARD) 200 MG TABLET 10	ENCIN (ENDOCAR	ENDOCARD	200 MG	10	TABLET	36.43	12	0.02%	0.02%	N	1.20			
26	EUFOX 200 MG TABLET 10	EUFOX	LUPIN LTD	200 MG	10	TABLET	43.93	55922.89	0.01%	0.01%	N	4.39			
27	EXVID 200 MG TABLET 10	EXVID	EXCARE LABORATORIES	200 MG	10	TABLET	10.35	349519.25	0.04%	0.04%	N	1.04			
28	FESTIVE 200 MG TABLET 10	FESTIVE	LABORATE PHARMACEUTICALS LTD	200 MG	10	TABLET	32.85	2169.1	0.00%	0.00%	N	3.28			
29	FIBAC 200 MG TABLET 10	FIBAC	CALIBAR PHARMACEUTICALS	200 MG	10	TABLET	37.85	134314.96	0.01%	0.01%	N	3.08			
30	FLIN 200 MG TABLET 6	FLIN	RKG PHARMA	200 MG	6	TABLET	18.46	8064.42	0.00%	0.00%	N	3.82			
31	FLOMED 200 MG TABLET 10	FLOMED	LYPHOMED REMEDIES P.LTD.	200 MG	10	TABLET	39.29	18815.91	0.00%	0.00%	N	3.89			
32	JONFLOX (DR.JOHNS) 200 MG TABLET 10	JONFLOX (DR.JOH	DR. JOHNS LABORATORIES PVT LTD	200 MG	10	TABLET	39.29	138767.48	0.02%	0.02%	N	3.89			
33	JONFLOX 200 MG TABLET 10	JONFLOX	PARION PHARMA LTD	200 MG	10	TABLET	39.58	12123.96	0.00%	0.00%	N	5.15			
34	JOX 200 MG TABLET 10	JOX	DR. JOHNS LABORATORIES PVT LTD	200 MG	10	TABLET	51.53	24588.39	0.00%	0.00%	N	1.05			
35	MEXAFLO 200 MG TABLET 10	MEXAFLO	NOVARTIS INDIA LTD	200 MG	10	TABLET	10.5	140736.8	0.02%	0.02%	N	3.57			
36	MINIMAX 200 MG TABLET 10	MINIMAX	DIAL PHARMACEUTICALS PVT. LTD.	200 MG	10	TABLET	35.72	138775.2	0.02%	0.02%	N	4.07			
37	MOFLOX 200 MG TABLET 10	MOFLOX	MARC PHARMA	200 MG	10	TABLET	40.71	9919.07	0.00%	0.00%	N	4.57			
38	NATAZOLICIN O 200 MG TABLET 10	NATAZOLICIN O	INDIAN DRUG & PHARMACEUTICALS LTD (IDPL)	200 MG	10	TABLET	45.71	45.71	0.00%	0.00%	N	4.33			
39	NEGDX 200 MG TABLET 10	NEGDX	MACMILON PHARMACEUTICALS	200 MG	10	TABLET	43.25	138127.89	0.02%	0.02%	N	1.10			
40	NICOFLOX (PHC) 200 MG TABLET 10	NICOFLOX (PHC)	ABSOTT HEALTHCARE PVT. LTD	200 MG	10	TABLET	10.95	16688091.58	1.93%	1.93%	Y	4.98	4.98		
41	NORLET-O 200 MG TABLET 10	NORLET-O	DR. REDDYS LABORATORIES LTD	200 MG	10	TABLET	49.82	9766.41	0.01%	0.01%	N	4.24			
42	NORMESIS 200 MG TABLET 10	NORMESIS	LUPIN LTD	200 MG	10	TABLET	42.4	476322.51	0.05%	0.05%	N	3.03			
43	NOVOFRAN 200 MG TABLET 10	NOVOFRAN	SEAGULL LABS (I) LTD	200 MG	10	TABLET	30.29	40.75	0.01%	0.01%	N	4.08			
44	O F K 200 MG TABLET 10	O F K	SIGNOVA PHARMA (P) LTD	200 MG	10	TABLET	36.57	182.85	0.00%	0.00%	N	3.88			
45	O RON 200 MG TABLET 10	O RON 200	NEURON PHARMA (P) LTD	200 MG	10	TABLET	57.86	87609.04	0.01%	0.01%	N	5.79			
46	OAK 200 MG TABLET 10	OAK	EXDTIC LABORATORIES PVT LTD	200 MG	10	TABLET	43.83	200256.52	0.02%	0.02%	N	4.28			
47	OBACTIN (MRD) 200 MG TABLET 10	OBACTIN (MRD)	MERIDIAN ENTERPRISES PVT LTD	200 MG	10	TABLET	35	328720	0.04%	0.04%	N	3.50			
48	OBAXTERIE 200 MG TABLET 10	OBAXTERIE	HESDE & HESDE	200 MG	10	TABLET	8.5	671.5	0.00%	0.00%	N	0.85			
49	OBID 200 MG TABLET 10	OBID	RADICURA PHARMA	200 MG	10	TABLET	59.15	26511535.65	2.81%	2.91%	Y	5.92	5.92		
50	OF 200 MG TABLET 10	OF	JB CHEMICALS	200 MG	10	TABLET									

51	OF IND 200 MG TABLET 10	OF IND	INDICA LABORATORIES PVT. LTD.	200 MG	10	TABLET	32.67	639.4	0.00%	0.00%	N	3.27
52	OFIAC 200 MG TABLET 10	OFIAC	ACCOSTS REMEDIES PVT LTD	200 MG	10	TABLET	39.52	43719.44	0.00%	0.00%	N	3.65
53	OFAL 200 MG TABLET 10	OFAL	HI TEC PHARMACEUTICALS PVT LTD	200 MG	10	TABLET	46.43	1495516.17	0.38%	0.38%	N	4.64
54	OFAST (PACIFIC) 200 MG TABLET 10	OFAST (PACIFIC)	PACIFIC DRUGS & CHEMICALS	200 MG	10	TABLET	44.63	45693.11	0.00%	0.00%	N	4.47
55	OFAX 200 MG TABLET 10	OFAX	OPHIO REMEDIES PVT LTD	200 MG	10	TABLET	42.34	148209.05	0.02%	0.02%	N	4.21
56	OFCL 200 MG TABLET 10	OFCL	REDSON LABORATORIES PVT LTD	200 MG	10	TABLET	37.34	2515.18	0.00%	0.00%	N	3.75
57	OFCONTA 200 MG TABLET 10	OFCONTA	JACINTA PHARMACEUTICALS PVT LTD	200 MG	10	TABLET	40.36	726.48	0.00%	0.00%	N	4.04
58	OFCOR 200 MG TABLET 10	OFCOR	CORDNA	200 MG	10	TABLET	36.07	3859.49	0.00%	0.00%	N	3.61
59	OFEXIN 200 MG TABLET 10	OFEXIN	EMBIOTIC LAB	200 MG	10	TABLET	51.07	1026762.35	0.13%	0.13%	N	5.11
60	OFFER 200 MG TABLET 10	OFFER	UDIK PHARMACEUTICALS	200 MG	10	TABLET	39.7	103.5	0.00%	0.00%	N	3.67
61	OFHL 200 MG TABLET 10	OFHL	RAMOSE LABORATORIES PVT. LTD.	200 MG	10	TABLET	37.3	205083.6	0.02%	0.02%	N	3.72
62	OFK 200 MG TABLET 10	OFK	MAKERS LABS	200 MG	10	TABLET	11	760016.38	0.03%	0.03%	N	1.20
63	OFKAB 200 MG TABLET 10	OFKAB	LANCER PHARMACEUTICALS PVT. LTD	200 MG	10	TABLET	39.2	39396	0.00%	0.00%	N	3.92
64	OFLA 200 MG TABLET 10	OFLA	KHANDISWAL LABORATORIES LTD	200 MG	10	TABLET	35	4608710	0.51%	0.51%	N	3.50
65	OFLACAD 200 MG TABLET 10	OFLACAD	ZYDUS CADILA - ZHL	200 MG	10	TABLET	11.5	471845.8	0.05%	0.05%	N	1.15
66	OFLACIN 200 MG TABLET 10	OFLACIN	MICRO LABS LTD	200 MG	10	TABLET	10.78	311981.48	0.03%	0.03%	N	1.08
67	OFIAC 200 MG TABLET 10	OFIAC	HEALTH CARE FORMULATIONS PVT. LTD.	200 MG	10	TABLET	37.6	3113392.8	0.34%	0.34%	N	3.78
68	OFIAMED 200 MG TABLET 10	OFIAMED	AGLOWMED PHARMACEUTICALS LTD.	200 MG	10	TABLET	35	459796	0.65%	0.65%	N	3.10
69	OFIAMD 200 MG TABLET 10	OFIAMD	LEFFORD HEALTHCARE	200 MG	10	TABLET	14.5	203	0.00%	0.00%	N	1.45
70	OFIAMEST 200 MG TABLET 10	OFIAMEST	BLINDR PHARMA	200 MG	10	TABLET	38.85	35284.88	0.00%	0.00%	N	3.89
71	OFILER 200 MG TABLET 10	OFILER	ARISTO PHARMACEUTICALS PVT LTD	200 MG	10	TABLET	53.26	28853866.78	3.17%	3.17%	Y	6.39
72	OFLEX 200 MG TABLET 10	OFLEX	FINECURE PHARMACEUTICALS	200 MG	10	TABLET	40.27	509182.61	0.06%	0.06%	N	4.03
73	OFLIN 200 MG TABLET 15	OFLIN	ZYDUS CADILA - ZHL	200 MG	15	TABLET	38.64	27729541.76	3.05%	3.05%	Y	5.81
74	OFLOACT OR 200 MG TABLET 10	OFLOACT OR	PRIVAS PHARMACEUTICALS	200 MG	10	TABLET	51.93	2119.03	0.00%	0.00%	N	5.19
75	OFLOBE 200 MG TABLET 10	OFLOBE	SAPENT	200 MG	10	TABLET	36.92	103575.7	0.01%	0.01%	N	3.69
76	OFLOCARE 200 MG TABLET 10	OFLOCARE	TABLETS INDIA LTD	200 MG	10	TABLET	34.62	276.96	0.00%	0.00%	N	3.46
77	OFLOCHEM 200 MG TABLET 10	OFLOCHEM	ZYDUS CADILA - ZHL	200 MG	10	TABLET	10	828437.7	0.00%	0.00%	N	1.00
78	OFLOFRESH 200 MG TABLET 10	OFLOFRESH	SMART LABORATORIES PVT LTD	200 MG	10	TABLET	17	573996	0.08%	0.08%	N	1.70
79	OFLOKEM 200 MG TABLET 10	OFLOKEM	AIKEM LABORATORIES LTD.	200 MG	10	TABLET	12	823505.3	0.07%	0.07%	N	1.20
80	OFLOKEM NCV 200 MG TABLET 10	OFLOKEM NCV	AIKEM LABORATORIES LTD.	200 MG	10	TABLET	11.83	1594253.01	0.17%	0.17%	N	1.18
81	OFLOMAC 200 MG TABLET 10	OFLOMAC	MACLEODS PHARMACEUTICALS PVT LTD	200 MG	10	TABLET	47.71	11824197.1	13.60%	13.60%	Y	4.77
82	OFLOMIL 200 MG TABLET 10	OFLOMIL	GLENMARK PHARMACEUTICALS LTD.	200 MG	10	TABLET	42	2523.44	0.00%	0.00%	N	4.20
83	OFLOPAR 200 MG TABLET 10	OFLOPAR	SHRINIVAS GUJARAT LABORATORIES PVT LTD	200 MG	10	TABLET	39.08	43354.88	0.03%	0.03%	N	3.91
84	OFLOSA 200 MG TABLET 10	OFLOSA	PERK PHARMA	200 MG	10	TABLET	31.5	157.5	0.00%	0.00%	N	3.15
85	OFLOSTAR(CO) 200 MG TABLET 10	OFLOSTAR(CO)	CADILA PHARMACEUTICALS LTD	200 MG	10	TABLET	9	64559.14	0.01%	0.01%	N	0.90
86	OFLOTAS 200 MG TABLET 10	OFLOTAS	INTAS PHARMACEUTICALS LTD	200 MG	10	TABLET	13.5	262420.15	0.03%	0.03%	N	1.35
87	OFLOTER 200 MG TABLET 10	OFLOTER	GUJARAT TERCE LABORATORIES LTD	200 MG	10	TABLET	40	2040	0.00%	0.00%	N	4.00
88	OFLOWAL 200 MG TABLET 10	OFLOWAL	WALLACE PHARMACEUTICALS LTD.	200 MG	10	TABLET	12	72096	0.00%	0.00%	N	1.20
89	OFLOWIN (MAKER) 200 MG TABLET 10	OFLOWIN (MAKER)	MAKERS LABS	200 MG	10	TABLET	44.32	282718.76	0.03%	0.03%	N	4.43
90	OFLOWOCK 200 MG TABLET 10	OFLOWOCK	WOCKHARDT LTD	200 MG	10	TABLET	10.2	897.6	0.00%	0.00%	N	1.02
91	OFLOX 200 MG TABLET 10	OFLOX	CIPLA LTD.	200 MG	10	TABLET	52.29	123969529.5	13.63%	13.63%	Y	5.23
92	OFLOX PLUS 200 MG TABLET 10	OFLOX PLUS	ZENTH HEALTHCARE LTD	200 MG	10	TABLET	39.58	493839.66	0.03%	0.03%	N	3.96
93	OFLUP 200 MG TABLET 10	OFLUP	LUPIN LTD	200 MG	10	TABLET	12.5	4900	0.00%	0.00%	N	1.25
94	OFNI 200 MG TABLET 10	OFNI	SUNH PHARMA PVT LTD	200 MG	10	TABLET	33.31	4846.5	0.00%	0.00%	N	3.33
95	OFPI 200 MG TABLET 10	OFPI	PSYCHOTROPICS INDIA LTD	200 MG	10	TABLET	12	924	0.00%	0.00%	N	1.20
96	OFPRON 200 MG TABLET 10	OFPRON	LEFFORD HEALTHCARE	200 MG	10	TABLET	13.81	171130.97	0.02%	0.02%	N	1.38
97	OFTEL (INTEL) 200 MG TABLET 6	OFTEL (INTEL)	INTEL PHARMACEUTICALS	200 MG	6	TABLET	15.64	1603.55	0.00%	0.00%	N	5.64
98	OFUM (PFD) 200 MG TABLET 10	OFUM (PFD)	PROFIC ORGANICS	200 MG	10	TABLET	34.48	726515.66	0.08%	0.08%	N	3.45
99	OFVISTA 200 MG TABLET 10	OFVISTA	ELDER PHARMACEUTICALS LTD	200 MG	10	TABLET	11	25720.5	0.00%	0.00%	N	1.10
100	OFX 200 MG TABLET 10	OFX	EMBIOTIC LAB	200 MG	10	TABLET	51.07	2587257.27	0.23%	0.23%	N	5.11
101	OGIT 200 MG TABLET 10	OGIT	COXSWAIN HEALTHCARE	200 MG	10	TABLET	41.43	40559.97	0.00%	0.00%	N	4.14
102	OGYRO 200 MG TABLET 10	OGYRO	AURX PHARMACEUTICALS PVT LTD	200 MG	10	TABLET	50.21	9188.43	0.00%	0.00%	N	5.02
103	OJEN 200 MG TABLET 10	OJEN	JENBURKT PHARMACEUTICALS LTD	200 MG	10	TABLET	38.93	1375630.48	0.15%	0.15%	N	3.89
104	OKS 200 MG TABLET 10	OKS	UNIMARCK HEALTHCARE LTD.	200 MG	10	TABLET	28.72	1112.64	0.00%	0.00%	N	2.87
105	OL (LEBEM) 200 MG TABLET 10	OL (LEBEM)	LEBEM LABORATORIES PVT LTD	200 MG	10	TABLET	23.63	2820239.09	0.22%	0.22%	N	2.38
106	OLIFE 200 MG TABLET 10	OLIFE	LIFE LINE BIOTECH LTD.	200 MG	10	TABLET	40	73560	0.01%	0.01%	N	4.00
107	OLIX 200 MG TABLET 10	OLIX	CIPLA LTD.	200 MG	10	TABLET	17.85	2333022.29	0.28%	0.28%	N	1.79
108	OLTAUR 200 MG TABLET 10	OLTAUR	Taurus LABORATORIES PVT LTD	200 MG	10	TABLET	40.97	14462.41	0.02%	0.02%	N	4.10
109	OLVEX 200 MG TABLET 10	OLVEX	KENTRECK LABS PVT. LTD.	200 MG	10	TABLET	44.17	221026.58	0.02%	0.02%	N	4.42
110	OMAX (ASTRON HEALTHCARE) 200 MG TABLET 10	OMAX (ASTRON HEALTHCARE)	ASTRON HEALTHCARE	200 MG	10	TABLET	14.6	12169	0.00%	0.00%	N	1.46
111	ONFLOX 200 MG TABLET 10	ONFLOX	LOGOS PHARMACEUTICALS	200 MG	10	TABLET	37.85	1783.55	0.00%	0.00%	N	3.80
112	ONOFF 200 MG TABLET 10	ONOFF	RANBAXY LABORATORIES LTD	200 MG	10	TABLET	14	776594	0.03%	0.03%	N	1.40
113	ONOVA XL 200 MG TABLET XL 10	ONOVA XL	PHARMASYNTH FORMULATIONS (P) LTD	200 MG	10	TABLET	20	4540	0.00%	0.00%	N	4.00
114	OPEC (SHRINIVAS OJ) 200 MG TABLET 10	OPEC (SHRINIVAS)	SHRINIVAS GUJARAT LABORATORIES PVT LTD	200 MG	10	TABLET	42.07	372824.34	0.04%	0.04%	N	4.21
115	OPHAR 200 MG TABLET 10	OPHAR	OPHAR LIFE SCIENCES PVT LTD	200 MG	10	TABLET	39.2	79380	0.01%	0.01%	N	3.92
116	OPRIS 200 MG TABLET 10	OPRIS	LEO LIFE SCIENCE PVT LTD	200 MG	10	TABLET	35.65	31902.62	0.00%	0.00%	N	3.57
117	OPTRA 200 MG TABLET 10	OPTRA	RENANCE FORMULATION PVT LTD	200 MG	10	TABLET	36.93	4133.73	0.00%	0.00%	N	3.69
118	OO 200 MG TABLET 10	OO	JB CHEMICALS	200 MG	10	TABLET	44.5	44.5	0.00%	0.00%	N	4.45
119	ORAPEN 200 MG TABLET 10	ORAPEN	MEDLEY PHARMACEUTICALS	200 MG	10	TABLET	11.58	2704.42	0.00%	0.00%	N	1.20
120	ORIBRO 200 MG TABLET 10	ORIBRO	WILSHIRE PHARMACEUTICALS PVT. LTD.	200 MG	10	TABLET	42.05	8746.4	0.00%	0.00%	N	4.21
121	OSON 200 MG TABLET 10	OSON	LINSON PHARMACEUTICALS	200 MG	10	TABLET	41	2388367.2	0.28%	0.28%	N	4.10
122	OTOX 200 MG TABLET 10	OTOX	FRANKLIN LABORATORIES (INDIA) PVT. LTD.	200 MG	10	TABLET	33	435991.96	0.05%	0.05%	N	1.30
123	OTRAS 200 MG TABLET 10	OTRAS	BIOSTRASS HEALTH SCIENCES	200 MG	10	TABLET	32	32	0.00%	0.00%	N	3.20
124	OWIN 200 MG TABLET 10	OWIN	ALEMISC LTD	200 MG	10	TABLET	60	5280	0.00%	0.00%	N	6.00
125	OXA(RA) 200 MG TABLET 10	OXA(RA)	RAVANI PHARMACEUTICALS PVT LTD	200 MG	10	TABLET	48.18	855963.73	0.10%	0.10%	N	4.82

